BerGenBio

Board/Management Information • Apr 11, 2022

BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer

BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer

Bergen, Norway, 11 April 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL inhibitors for severe

unmet medical needs, today announces the appointment of Cristina Oliva, MD as

Chief Medical Officer (CMO), effective 25 April 2022. Cristina joins the senior

leadership team heading up clinical development of BerGenBio's selective AXL

inhibitor programs.

Cristina is a Board-certified oncologist and brings over 20 years of senior

clinical development experience across large pharmaceutical, biotechnology and

Clinical Research Organizations (CROs). Most recently Cristina was Vice

President, Oncology and Head of Oncology Centre of Excellence at IQVIA Ltd,

where she led the development of decentralized trials and established and led

the IQVIA Oncology Global Scientific Advisory Board. Prior to her role at IQVIA,

Cristina held senior positions leading oncology development programs for Nordic

Nanovector, Takeda Pharmaceuticals, GlaxoSmithKline and Eli Lilly.

Martin Olin, Chief Executive Officer of BerGenBio, commented: "I'm delighted to

welcome Cristina as our new Chief Medical Officer. Cristina's leadership

experience within oncology drug development across big pharma, biotech and CRO

environments will be instrumental in executing BerGenBio's development strategy

for our AXL inhibitor programs, including our most advanced program bemcentinib,

currently in phase II trials."

On her appointment as Chief Medical Officer at BerGenBio, Cristina Oliva, MD,

commented:"BerGenBio is on the frontier of developing novel, highly selective

AXL inhibitors for the treatment of severe diseases such as oncology and

respiratory infections. I'm very excited to join BerGenBio at this critical

phase and look forward to working with the senior leadership team to help

further advance its AXL inhibitor programs."

Contacts:

For BerGenBio: Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II clinical development

programme focused on combination and single agent therapy in cancer and COVID

-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is

undergoing phase I clinical testing.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Suchrisks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.